Haemophilia treatment: where to from here? Have the risks increased?
作者信息
Faed Jim
出版信息
N Z Med J. 2003 Aug 22;116(1180):U559.
PMID:14581981
Abstract
摘要
相似文献
1
Haemophilia treatment: where to from here? Have the risks increased?
N Z Med J. 2003 Aug 22;116(1180):U559.
2
Pharmacoeconomic impact of obesity in severe haemophilia children on clotting factor prophylaxis in a single institution.
Haemophilia. 2011 Jul;17(4):717-8. doi: 10.1111/j.1365-2516.2010.02462.x. Epub 2011 Feb 16.
3
The challenge arising from the cost of haemophilia care: an audit of haemophilia treatment at Auckland Hospital.
N Z Med J. 2003 Aug 22;116(1180):U561.
4
Towards a partnership of care for patients with haemophilia.
N Z Med J. 2003 Dec 12;116(1187):U721.
5
Utilization patterns and associated costs of factor assistance programmes among persons with haemophilia: a single institution review.
Haemophilia. 2012 May;18(3):e95-e100. doi: 10.1111/j.1365-2516.2011.02649.x. Epub 2011 Sep 13.
6
Managing hemophilia: safer, more effective but expensive.
J Ark Med Soc. 2004 Aug;101(2):50-1.
7
Cost related to replacement therapy during hospitalization in haemophiliacs with or without inhibitors: experience of six French haemophilia centres.
Haemophilia. 2002 Sep;8(5):674-9. doi: 10.1046/j.1365-2516.2002.00671.x.
8
Treatment of hemophilia in developing countries: a journey of a thousand miles.
Pediatr Blood Cancer. 2010 Mar;54(3):348-9. doi: 10.1002/pbc.22360.
9
Setting research priorities to improve cost-effectiveness estimations of primary prophylaxis with clotting factor for people with severe haemophilia.
Haemophilia. 2004 Mar;10 Suppl 1:58-62. doi: 10.1111/j.1355-0691.2004.00880.x.
10
Costs and utilization of hemophilia A and B patients with and without inhibitors.
J Med Econ. 2014 Nov;17(11):798-802. doi: 10.3111/13696998.2014.953679. Epub 2014 Aug 20.
Zotero 插件